Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipid bupivacaine TAP block vs conventional bupivacaine for pain and sleep after laparoscopic colorectal cancer surgery in elderly patients
ChiCTR2300075117Phase 4Not yet recruiting
- Sponsor
- General Hospital of Ningxia Medical University
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bupivacaine in colorectal cancer (CRC) (2 arms), sponsored by General Hospital of Ningxia Medical University. Primary endpoint: Area under the curve of resting pain and movement pain scores from 12 to 72 hours after surgery. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
bupivacaine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2300075117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075117.